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ABSTRACT 
 
 
Background 
Female stress urinary incontinence (SUI) greatly affects quality of life.  The 
midurethal sling (MUS) procedure has been widely accepted as the standard of 
care treatment for SUI, although there is little information regarding patients’ 
subjective reports of symptom improvement. 
 
Objectives 
The objective of this study was to identify clinical and demographic 
characteristics that predict subjective symptom improvement following MUS 
procedures in women with SUI. 
 
Materials and Methods 
The study design was retrospective cohort.  Subjects included women who 
underwent MUS between 2006 and 2008, returned mailed surveys and met our 
predefined inclusion criteria. Pre-operative data included demographics, prior 
surgery, co-morbid diseases, urodynamics and concomitant reconstructive 
surgery. Subjective improvement was measured by score improvement on the 
UIQ-7, UDI-6, the UDI stress subscale and Question 3 of the UDI, “Do you 
experience urine leakage related to physical activity, coughing, or sneezing?”   
 
vi 
 
 
 
Results 
The mean age of the study sample was 57 years, parity was 2.5 and BMI was 
28.  Subjects with lower MUCP demonstrated more improvement on the UIQ-7.  
ΔUDI-6 stress subscale scores were more sensitive to symptom change than 
either the ΔUDI-6 or ΔUIQ-7.  Older, menopausal subjects with urethral 
hypermobility and concomitant vaginal suspension showed less improvement 
than subjects without these characteristics.  After controlling for urethral straining 
angle, PVR, menopause and time out from surgery, older age and concomitant 
vaginal suspension were associated with persistent post-op symptoms on the 
UDI-6 Question 3 and age remained the only variable associated with persistent 
symptoms on the UDI-6 stress subscale. 
 
Conclusion 
Concurrent vaginal suspension and advancing age were risk factors for 
persistent symptoms following MUS procedures in patients with SUI.  Symptoms 
may recur after 24 post-operative months.  Clinicians are encouraged to provide 
additional preoperative counseling to those women who are at greatest risk for 
persistent symptoms. 
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CHAPTER I 
1 Introduction 
1.1 Description of the medical condition 
 
Female stress urinary incontinence (SUI) is the involuntary transurethral loss of 
urine at the moment of increased intra-abdominal pressure.  Upwards of 70% of 
women suffer from urinary incontinence during their lifetime and many undergo 
surgical treatment for this condition.1  Traditional surgical procedures include the 
Marshall-Marchetti Krantz colposuspension, the Burch urethropexy, various 
needle suspension procedures and the pubovaginal sling.2-6  The pubovaginal 
sling (made with either fascia lata or synthetic mesh) involves placing the 
suspension material at the urethrovesical junction (UVJ).  The newer midurethral 
sling (MUS) procedures, first introduced by Ulmsted and Petros in 1995 
(retropubic) and then modified by Delorme in 2001 (transobturator), have 
revolutionized the treatment of SUI with improved efficacy and reduced 
morbidity.7-9  While a number of studies have examined objective outcomes 
following MUS, relatively fewer have addressed patients’ reports of subjective 
symptom improvement.10-12 
 
1.2 Overview of research problem 
 
While there are several pathophysiologic mechanisms that may contribute to the 
development of SUI, there is no consensus about the relative importance of each 
of these in predicting successful surgical outcome.  Loss of periurethral 
11 
 
 
 
connective tissue can result in urethral hypermobility, which is the demonstrable 
(>30°) rotational descent of the urethrovesical junction (UVJ) during a Valsalva’s 
maneuver.13  This is measured via a cotton swab test, noting the angle of the Q-
tip with respect to the horizontal, at rest and during straining.14  Shorter functional 
urethral length and the presence of intrinsic sphincter deficiency (ISD), 
diagnosed by low maximum urethral closure pressure (MUCP) or abdominal leak 
point pressure (LPP), may also be associated with reduced symptom 
improvement.15, 16 
 
Other preoperative predictors of MUS success have been increasingly explored 
in the urogynecology literature, with little consensus.  Some studies have found 
advanced age, menopausal status, prior anti-incontinence surgery, and urinary 
urgency to be independently associated with sling failure, whereas others have 
failed to find predictors of clinical failure.11, 17, 18  Interpretation of the published 
literature is difficult due to the lack of consistent measures of clinical variables, 
differences in the size and characteristics of the various study populations, and 
definitions of treatment success and/or failure. 
 
1.3 Quality of Life instruments as outcome measures 
 
Much of the existing literature evaluating the efficacy of midurethral slings in 
patients with SUI has used an objective measure of cure, the cough stress test 
(CST), performed with a subjectively full bladder or 300mL, whichever is less.  
12 
 
 
 
While this test may provide a consistent tool for research, it is not always a 
reliable assessment of patients’ daily symptoms.  Patients who present 
postoperatively complaining of persistent incontinence deserve a thorough 
evaluation and treatment plan, even if they have a negative CST.  In contrast, 
patients who are subjectively cured, but leak during a research-driven CST, 
generally do not need further evaluation.  This common clinical paradox has 
prompted the selection of patient-reported subjective outcomes.  Two validated 
quality of life (QOL) questionnaires were selected for use in the present study 
because of their prevalent use in clinical outcomes research and because of their 
ability to isolate different types of incontinence symptoms: the Pelvic Floor 
Distress Inventory (PFDI-20) and the Pelvic Floor Impact Questionnaire (PFIQ-
7).19  The urinary subscales of these instruments (UDI-6 and UIQ-7) were used to 
assess post-operative subjective satisfaction.20, 21 
13 
 
 
 
CHAPTER II 
 
2 Related work 
2.1 Measuring urethral hypermobility 
 
In the early 1970’s bead-chain cystometrograms were performed to evaluate 
urethral and bladder neck mobility using fluoroscopy.22  The urethra was 
prepared by applying lidocaine jelly with a cotton swab.   During one of these 
routine procedures, Crystle et al observed the dynamic deviation of the cotton 
swab concurrent with the patient’s Valsalva’s maneuver, and the “Q-tip test” was 
born.14  The inexpensive and less invasive Q-tip test soon replaced more 
cumbersome measures of urethral mobility and a somewhat arbitrary cut-off of 
30˚ categorized patients as having a “hypermobile” urethra.23 
 
An assessment of urethral hypermobility (UHM) has been universally integrated 
into the evaluation of female urinary incontinence.24  Efforts to standardize the Q-
tip test suggest that precise placement of the cotton swab at the urethrovesical 
junction (UVJ) is the most critical factor.25  Bladder volume, presence of detrusor 
overactivity and presence of a cystocele do not affect the measured straining 
angle.  Replacement of the cotton swab with a straight urethral catheter yields 
reduces angles of excursion, and thus, these techniques are not 
interchangeable.26 
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Despite significant efforts to standardize this simple test, adherence to these 
endorsed standards is inconsistent.27-29  In addition, the specific method of 
measuring the angle has not been standardized (straining angle vs. straining 
minus resting angle) and various methods are utilized in the published literature.   
 
2.2 Effect of urethral hypermobility on urinary incontinence 
 
Urethral hypermobility was implicated in the pathophysiology of stress urinary 
incontinence long before the development of the MUS procedure.  The efficacy of 
the retropubic suspension procedures provided some evidence that relocation of 
the urethra in an abdominal and retropubic position was the key to continence.2-5  
However, the traditional pubovaginal sling incorporated tensioned suburethral 
support, thus providing sufficient coaptation of the urethral lumen to overcome 
increased intravesical pressure during straining and prevent stress incontinence.6 
The Integral Theory of incontinence supports this principle, suggesting that 
kinking of the urethra is the most effective means of achieving continence.30 
 
2.3 Effect of urethral hypermobility on surgical outcomes 
 
Urethral hypermobility may simultaneously contribute to the development of SUI 
and play a key role in achieving post-operative continence.18, 29, 31-34  Yet, the 
categorical declaration of urethral mobility, as hypermobile or normal, remains a 
topic of interest.  A recent prospective study of 134 women undergoing TO MUS 
15 
 
 
 
demonstrated that subjects with a Q-tip angle less than 45˚ had significantly 
greater postoperative incontinence.34 A longitudinal cohort of 306 women 
followed over 20 years after pubovaginal sling found that incontinence cure rates 
were 96% for those with preoperative UHM, compared to 74% for those without 
UHM.35  This evidence suggests that while a greater urethral straining angle may 
contribute to SUI, it is difficult to ascertain how the extent of that mobility affects 
post-operative continence. 
16 
 
 
 
CHAPTER III 
 
3 Details of research 
 
Using a cross-sectional survey design, an eligible cohort was identified and a 
retrospective chart review performed. 
3.1 Subject selection 
 
The UMass Memorial Medical Center hospital surgical log was used to identify 
women who underwent an MUS procedure for SUI between May, 2006 and 
December, 2008 by four fellowship-trained surgeons.  The start date 
corresponded with the implementation of standardized preoperative UDI-6 and 
UIQ-7 questionnaires in this full-time academic urogynecology practice setting.  
Retropubic MUS procedures (RP) were all performed using the “bottom-up” 
approach (Tension-free Vaginal Tape, Gynecare, Ethicon Inc, Somerville, NJ or 
AdvantageFit, Boson Scientific, Natick, MA).  The transobturator procedures (TO) 
included the “outside-in” approach (Monarc, American Medical System, 
Minnetonka MN or Obtryx, Boson Scientific, Natick, MA), following the 
manufacturer’s instructions. 
 
In July, 2009, with Institutional Review Board approval, all potentially eligible 
women were mailed a survey packet which included the PFDI-20, the PFIQ-7, 
and a return-addressed stamped envelope.19  (Data from the non-urologic survey 
subscales were used for a different study.)  Once the surveys were returned, the 
17 
 
 
 
charts of study participants were reviewed using a standardized case report form.  
At the time of the chart review, subjects were selected for inclusion if they were 
English-speaking, had an operative note confirming that a MUS was performed, 
were diagnosed as having Stages I-III prolapse and completed the QOL surveys 
pre-operatively.  Stage IV prolapse patients were excluded due to difficulty 
measuring UHM, greater likelihood of urinary retention, and occult SUI.  Patients 
who underwent a concomitant vaginal obliterative procedure were also excluded, 
as most were undergoing MUS for occult SUI, and thus were asymptomatic 
preoperatively.  Patients who underwent an additional anti-incontinence 
procedure following the index MUS were also excluded, since their current 
survey results would not reflect their post-MUS symptoms.  A HIPAA waiver 
(Appendix C) granted by the UMass IRB allowed for a chart review of a random 
sample of non-responders. 
 
3.2 Objective data collection 
 
For purposes of assessing the representativeness of our responding patient 
sample, data collected from medical records included patient demographics, past 
medical and surgical history (at the time of the surgical consult) including prior 
SUI and prolapse repairs and preoperative urodynamic test results.  Patients 
were categorized as having diabetes (receiving hypoglycemic medication), 
neurologic disease (multiple sclerosis, spinal stenosis, stroke with deficit), or 
pulmonary disease (asthma, chronic cough, COPD), based on the review of 
18 
 
 
 
information contained in hospital charts.  Medications listed were reviewed and 
recorded if they included adrenergic (α or β receptor activity), anticholinergic 
(receptor) or diuretic pharmacologic activity, as these can impact urine 
production and/or bladder function.  Urodynamic data included cough stress test 
results (CST), evidence of detrusor overactivity (DO), post-void residual (PVR), 
MUCP and LPP.  Subjects without objective incontinence during the LPP test 
were not included in the ISD analysis.  Urinary retention was defined as PVR > 
100cc.  ISD was defined and evaluated separately as MUCP ≤ 20cmH20 or LLP 
≤ 60cmH20.13  Prolapse severity was documented by either the Baden/Walker 
system or the pelvic organ prolapse quantification system (POP-Q), as noted in 
the chart.36, 37  The decision to perform a RP MUS or TO MUS was based on 
attending physician preference.  Concomitant surgeries listed in the operative 
report were also recorded. 
 
Urethral angle measurements were performed with the standard Q-tip test, in 
which the cotton tip is placed at the urethrovesical angle (by retracting the Q-tip 
until resistance was encountered) in an empty bladder while the patient is resting 
in the dorsal lithotomy position.25  The angle of the Q-tip with respect to the 
horizontal was measured at rest and during maximal Valsalva effort without 
reduction of prolapse.  The straining and the resting angles were reported, and 
the straining minus resting (S-R) angle was calculated as a continuous variable.  
19 
 
 
 
Due to inconsistencies in the published literature, urethral hypermobility (UHM) 
was defined in two ways, as either straining angle ≥ 30˚ or S-R angle ≥ 30˚. 
3.3 Subjective symptom measurement 
 
Patient-reported subjective outcomes were assessed using published guidelines 
for calculating the UDI-6 and UIQ-7 scores (0-100, where 0 is asymptomatic and 
100 is maximally symptomatic).19  The UDI-6 can be divided into three subscales: 
Irritative Symptoms, Obstructive/Discomfort, and Stress Symptoms.  We 
performed an additional analysis of the UDI-6 stress subscale (Questions 3 and 
4) as well as Question 3 alone, to assess the independent contribution of these 
questions to symptom assessment.  All outcomes used the same scale, range 0-
100.  Question 3 reads, “Do you experience urine leakage related to physical 
activity, coughing, or sneezing?”  Question 4 reads, “Do you usually experience 
small amounts of urine leakage (that is, drops)?”  The difference between the 
post-op scores and the pre-op scores on both of these instrument subscales 
were calculated and was represented by “ΔUDI-6”, “ΔUIQ-7”, “ΔUDI-6 stress 
subscale” and “ΔQ3”.  Thus, a very negative “Δ” score indicates significant 
improvement in patient’s symptoms.  
 
3.4 Statistical analysis 
 
Descriptive statistics compared potential differences between survey responders 
and non-responders in several demographic and preoperative clinical 
20 
 
 
 
characteristics.  Table 4.1 lists all the variables investigated as potential 
predictors of the four outcome variables.  A total of thirty-six were considered.  
Continuous variables were compared with Student’s t-tests and categorical 
variables were compared using Pearson’s X2 test.  To analyze the crude 
association of each of the preoperative predictors with the four primary study 
outcomes ΔUDI-6, ΔUIQ-7, ΔUDI-6 stress subscale and ΔQ3, univariate linear 
regression was used.  Pairwise correlations were estimated for the four 
outcomes, as well as for the significant predictors identified by the univariate 
analysis.  For those variables that showed significant correlation, interaction 
variables were used to determine the relative association of individual potential 
predictors on each of the outcomes.  Multivariable normal theory regression 
modeling was developed to explore the associations with pre and post-operative 
changes in self-reported symptoms.  Variables identified during univariate 
analysis having P ≤ 0.10 were included in the regression models.  Several 
variables (PVR, MUCP, LPP, and UHM) were evaluated as both continuous and 
dichotomous variables, as described previously.  Statistical analysis was 
performed using Stata 10.0 statistical software (StataCorp, College Station, TX). 
21 
 
 
 
CHAPTER IV 
 
4 Results 
4.1 Study sample 
 
A total of five hundred and fifty-one patients were identified by surgical codes as 
having undergone a MUS procedure during the study period and were sent the 
survey packet in July, 2009.  Of the 225 responses (40% response rate), 37 were 
excluded (14 for vaginal obliteration, 8 for inappropriate identification as having 
an MUS, 7 for repeat anti-incontinence procedure since the index MUS, 4 for 
procidentia [Stage 4 prolapse], and 4 for lack of pre-op survey), leaving 188 
charts available for analysis (Figure 4.1).  A random sample of non-responders 
(n=38) was selected and their charts reviewed for comparison.  The non-
responders were more likely to have diabetes and prior urethral bulking whereas 
more responders underwent concomitant vaginal suspension (Table 4.1). 
 
The surveys were returned an average of 26 (range 4-84) months following initial 
urodynamic evaluation at consultation and 21 months (range 7-39) following the 
MUS procedure.  The subjects in the study sample were, on average, 56 years 
old, with a BMI of 28 and parity of 2.5.  Nearly two-thirds of the women were 
menopausal and almost half underwent an anterior repair or vaginal suspension 
at the time of the MUS. There was no difference in any concomitant 
urogynecologic surgery between subjects who had a RP MUS versus a TO MUS 
22 
 
 
 
(data not shown).  Preoperative average UDI-6, UIQ-7, UDI-6 stress subscale 
and Q3 scores were not different between those who underwent RP MUS vs. TO 
MUS. The average scores of the respondents are shown in Figure 4.2 and Table 
4.2.  The length of office-visit follow-up also did not differ between the responders 
and non-responders (average 6 months).   
 
4.2 Univariate analysis 
4.2a UDI-6 and UIQ-7 scores 
 
The average post-operative survey scores yielded an average improvement of 22 
points on the UDI-6 and UIQ-7, 40 points on the UDI-6 stress subscale, and 45 
points on Q3.  The results of the univariate analyses for each outcome are shown 
in Tables 4.3 – 4.4.  None of the selected pre-operative subject characteristics 
were crudely associated with a significant difference in UDI-6 scores.  Subjects 
with lower MUCP (and with objective ISD) demonstrated more improvement on 
the UIQ-7, scoring, on average, 20 points lower than those without ISD. 
 
4.2b UDI-6 stress subscale scores 
 
The distribution of ΔUDI-6 stress subscale scores included more episodes of 
symptom improvement than either the ΔUDI-6 or ΔUIQ-7, as post-operative 
scores were almost 20 points lower on this scale.  Older, menopausal subjects 
with urethral hypermobility (as measured by S-R) and concomitant vaginal 
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suspension showed less improvement on the ΔUDI-6 stress subscale than 
subjects without these characteristics.  Age and menopausal status were highly 
correlated (0.71); hence, a single variable was defined using four levels: 1 
(referent) = age < 55 and premenopausal (n=65), 2 = age < 55 and menopausal 
(n=23), 3 = age 55-64 (n=52), 4 = age ≥ 65 (n=46).  Only three subjects in the 
third age group were reported as menopausal.  As a result, Group 3 was 
comprised of all women within that age range, regardless of menopausal status.  
All women 65 years and older were considered to be menopausal.  This 
summary variable was evaluated for its association with ΔUDI-6 stress subscale, 
showing no difference between Group 2 and the referent group, inasmuch, 
menopausal status was not included in the regression model.  Comparison of 
Groups 3 and 4 to the referent group confirmed that older age was significantly 
associated with persistent symptoms. 
 
Table 4.5 shows that concomitant vaginal suspension conferred a statistically 
significant risk of persistent symptoms on ΔUDI-6 stress subscale (+20 point 
difference).  Greater urethral angle measurement on the Q-tip test (S-R) was 
significantly associated with greater subjective improvement.  Similarly, the 
diagnosis of UHM by S-R ≥ 30˚ predicted a 20 point improvement in the UDI-6 
stress subscale score.  There was a negative correlation between age and UHM.  
Ninety-two percent of women aged < 55 years had UHM, whereas only 60% of 
women in the two older age categories had UHM.  Therefore, these three groups 
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(< 55 yrs with UHM [n=7]), ≥ 55 yrs with UHM [n=27], ≥ 55 yrs without UHM 
[n=27]) were compared to measure the relative impact of age and UHM on the 
ΔUDI-6 stress subscale.  Older subjects reported more symptoms (+22 points, 
95%CI [5, 38] and P=0.01) than their younger counterparts, whereas similarly 
aged subjects who differed on UHM reported similar scores on the UDI-6 stress 
subscale (P=0.9). 
 
4.2c UDI-6 Question 3 scores 
 
Each of the factors older age, menopausal status, absence of UHM and 
concomitant vaginal suspension were statistically significantly associated with 
less subjective improvement on Q3 alone (Table 4.6).  In addition, subjects with 
elevated PVR reported less improvement on Q3, but not when PVR was coded 
as the dichotomous variable “retention” (PVR > 100cc).  For all outcomes, the 
effects of menopausal status and preoperative UHM on subjective improvement 
were modest compared to that of advancing age. 
 
4.3 Consideration for duration of follow-up 
 
The post-operative surveys were distributed at a single point in time, yielding a 
large range of duration of follow-up (average 21 months, range 7-39 months).  
Due to this significant variation, additional analyses were performed to determine 
if there was an association between symptom score and follow-up interval 
(Tables 4.7-4.9).  All correlation coefficients between months of subjective follow-
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up and the four outcome measures were less than 0.25.  Tertiles were formed 
dividing the duration of follow-up into three clinically relevant groups: short term ≤ 
12 months (referent group, n=35), medium term = 13-24 months (n=85) and long 
term ≥ 25 months (n=68).  Completion of the survey greater than 24 months from 
the index MUS was associated with less improvement on the UDI-6, UDI-6 stress 
subscale and UDI-6 Question 3.  Medium term (12-24 months) follow-up was 
also associated with persistent symptoms on the UDI-6 stress subscale.  There 
was no association between follow-up interval and symptom score, as measured 
by ΔUIQ-7. 
 
4.4 Multivariable analysis 
 
Variables considered in multiple prediction models included those variables 
found to be significant on univariate analysis with a P value < 0.10 with regard to 
a score difference on each of the four outcomes.  Three different models were 
created; one for ΔUIQ-7, ΔUDI-6 stress subscale and ΔQ3.  Preoperative ISD 
(determined by MUCP < 20cmH20) remained significantly associated with 
symptom improvement, as measured by the UIQ-7 (Table 4.7).  Pulmonary 
disease retained its significant association with persistent symptoms on the UIQ-
7.  After controlling for menopause, PVR, and UHM, advanced age and 
concomitant vaginal suspension were associated with persistent symptoms on 
the UDI-6 Question 3.  However, after controlling for these same factors for the 
UDI-6 stress subscale, only advanced age remained significant (Tables 4.8 and 
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4.9).  Multivariable analysis for all UDI-6 subsets (ΔUDI-6, ΔUDI-6 stress 
subscale and ΔUDI-6 Question 3) showed that a longer interval between the 
MUS procedure (>24 months) and completion of the QOL instrument was 
associated with less symptom improvement. 
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CHAPTER V 
5 Discussion 
5.1 Summary of findings 
 
In this cohort of women undergoing MUS, advanced age and concomitant 
vaginal suspension were statistically significant risk factors for persistent patient-
reported symptoms of SUI following MUS.  As the interval increased between the 
MUS procedure and completion of the survey, scores on the UDI-6 demonstrated 
significantly greater SUI symptoms.  A greater urethral angle during straining and 
UHM (angle ≥ 30˚) were associated with statistically significantly greater 
symptom improvement on univariate analysis, but these variables no longer 
retained their significance after controlling for age. 
 
5.2 Comparison to published data 
 
There is a growing body of literature investigating factors associated with 
treatment success following MUS procedures.10, 27, 38-41  Early studies lacked 
sufficient sample size to provide definitive findings about the role of demographic 
factors and urodynamic parameters.  More recent studies have been larger, but 
there remains a large variety of outcome measures examined in these 
investigations and inconsistencies in defining surgical cure or failure.12, 15, 34, 42  A 
discussion of the current literature accompanies each topic below. 
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5.3 Selection of appropriate subjective outcome measures 
 
Implementation of dichotomous outcomes (“success” or “failure”) does not 
capture the important finding of subjective improvement since it is confined to a 
strict definition of cure.  The UDI-6 is a well-recognized and frequently utilized 
instrument, which assesses urinary incontinence symptom distress. The UIQ-7 
evaluates the life impact of these symptoms on women.  Both instruments 
address a unique perspective of female urinary incontinence, and thus are not 
interchangeable.  Score improvement on the UDI-6 and UIQ-7 showed moderate 
correlation; indicating that, in this cohort, symptom bother and life impact were 
essentially the same. 
 
There is growing support for the use of the UDI-6 stress subscale and Q3 alone 
for purposes of assessing symptom change, due to their high sensitivity for SUI 
symptoms.15, 17  Many patients experience temporary urinary urgency and urge-
associated incontinence following the MUS procedure, and both are captured by 
the UDI-6.  Our data suggest that administration of the UDI-6 stress subscale 
may facilitate a more accurate interpretation of post-operative SUI symptom 
improvement since this instrument specifically address SUI symptoms.  Stav et al 
incorporated elements of several validated QOL instruments into a shorter 
questionnaire designed to address several outcomes of interest, effectively 
reducing patient survey burden.15  While this shorter hybrid questionnaire did use 
Question 3 from the UDI-6, it was not independently validated.  Administration of 
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the complete UDI-6 facilitates a more thorough subjective evaluation of patients’ 
urinary symptoms, but research efforts may benefit from a more focused analysis 
on the relevant symptom subscales. 
5.4 Advancing age 
 
Women undergoing surgical treatment for SUI span a wide age-range.9  There 
have been varying reports in the literature regarding the adequacy of treatment in 
elderly women.  In an ancillary analysis of data obtained from a randomized 
controlled trial comparing RP and TO MUS, advancing age was found to be an 
independent predictor of SUI treatment failure at one year.17  While some studies 
have found equal treatment effect in the elderly, those studies that include a 
broad range of ages more consistently show decreased efficacy with advancing 
age. 40, 43-46  There are several possible physiologic factors explaining these 
findings.  Estrogen receptors in the vaginal wall and bladder base allow 
circulating estrogen to increase blood supply and increase thickness of 
surrounding connective tissue.47  This may provide some stability to the UVJ and 
the continence mechanism.  Additionally, age-related decline in striated muscle 
and connective tissue can contribute to the development of incontinence.11, 48 
 
5.5 Concomitant prolapse procedures 
 
Similar to a 2008 study evaluating the association between MUS and post-
operative QOL and sexual function, we attempted to enhance the interpretability 
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of treatment outcome by using a QOL score improvement measure.49  However, 
we elected to include all MUS procedures at our institution, regardless of 
concomitant prolapse surgery.  This design provided insight into the impact of 
prolapse surgery on MUS outcomes, since these procedures are commonly 
performed together. 
 
In contrast to some reports, our data suggests that concomitant vaginal 
suspension is a risk factor for reduced efficacy of MUS procedures.15, 50  All of the 
vaginal suspension procedures in our patient population underwent the high 
uterosacral suspension.51  While others have hypothesized that prolapse repairs 
may restore the continence mechanism, our findings suggest that manipulation of 
the urethrovesical angle, with suspension of the vaginal apex, may actually over-
correct urethral hypermobility.   
 
5.6 Urethral hypermobility 
 
Subjects with elevated Q-tip angles and with de-facto UHM reported significantly 
better improvement following their MUS procedure than those with a more stable 
urethra.  Among subjects who underwent a vaginal suspension, preoperative 
UHM was associated with a greater (21 point) score improvement.  In contrast, 
among subjects with UHM, there was no difference in symptom improvement 
following MUS without suspension.  This finding is consistent with the published 
data reporting a greater incontinence cure rate following pubovaginal sling 
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among subjects with UHM and complicated SUI.35  As evidenced by these data, 
urethral hypermobility continues to have a place in clinical evaluation and the 
surgical consent process. 
 
5.7 Body mass index 
 
While some studies have shown that BMI is a significant risk factor for sling 
failure, especially for the very obese (BMI >35), our results do not support these 
findings.   Additional analysis with standard BMI categories (normal weight 18.5-
24.9, overweight 25-29.9, obese 30-34.9, morbidly obese > 35) still did not 
identify this as an independent risk factor for subjective failure on any of the 
outcome measures.  While this study was not powered specifically to show a 
difference in BMI, other larger studies share our findings.15, 52 
 
5.8 Intrinsic sphincter deficiency 
 
We did not find any association between symptom improvement and type of 
MUS performed or prior urogynecologic surgery.  There was an association of 
urethral sphincter function to the ΔUIQ-7, as measured by MUCP, expressed as 
both a continuous or dichotomized variable, and this relationship retained its 
magnitude and significance in multivariable analysis.  In our practice, MUCP is 
more commonly used to assess urethral function and differed significantly for 
subjects who had a RP MUS versus a TO MUS.  Interestingly, ISD in this cohort 
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was associated with improved UIQ-7 scores; this is in contrast to previously 
published literature.53  Direct comparisons of preoperative UIQ-7 and ΔUIQ-7 
scores were not different between RP MUS and TO MUS subjects, leaving 
uncertainty about the explanation of improved scores in subjects with ISD. 
 
5.9 Midurethral sling durability 
 
The durability of surgical treatment for SUI has been widely studied.10, 53-55  A 
randomized controlled trial of RP MUS versus TO MUS showed that the average 
time to develop recurrent symptoms was approximately 19 months for both 
procedures.54  We found that our RP MUS group had increasing UDI-6 stress 
subscales scores over time, as compared to the TO MUS group.  This was not 
due to measurably worse disease, as these two groups did not differ on pre-op 
UDI-6 scores. 
 
Across the entire cohort, the UDI-6 survey scores reflected significantly greater 
symptoms as the post-operative interval increased.  Without surveys at several 
post-operative intervals, it is difficult to determine if these higher scores reflected 
persistent or recurrent symptoms.  Interestingly, the UIQ-7 scores did not follow 
this same trend.  In fact, as the post-operative duration increased, subjects 
reported less interference of their bladder symptoms on their quality of life.  The 
UDI-6 scores increased by greater than 1 point per month, resulting in a 31 point 
increase in symptom severity after 2 years.  Based on the 25 point score 
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difference between bother categories on the UDI-6 stress subscale, a 31 point 
score increase translates to a significant change in patient’s bother category.  
These findings suggest that patients should be counseled about recurrence of 
symptoms following MUS. 
 
5.10 Study strengths and limitations 
 
This study has several important strengths, including the use and comparison of 
validated QOL outcome measures.  Since SUI is largely a QOL concern, 
subjective measures of how much patients are bothered by their symptoms and 
impact on life’s activities are perhaps the most appropriate.  Because our study 
population included several different MUS types, performed in a typical academic 
urogynecologic practice with limited exclusion criteria, our results are likely to be 
generalizable to similar practices.  The primary limitations of the present study 
are the low response rate, differences between survey responders and a random 
sample of non-responders, and the retrospective nature of data collection.  In 
addition, cross-sectional administration at various post-operative intervals 
introduced a strong confounder.  As clinician-researchers struggle to compare 
the effects of different treatment strategies, there has been increased attention 
given to the relationships between subjective and objective outcome measures.  
Standardized subjective assessment at regular postoperative intervals would 
provide more information about treatment durability. 
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5.11 Study conclusions and future research directions 
 
In conclusion, concurrent vaginal suspension and advancing age were risk 
factors for persistent symptoms following MUS procedures in patients with SUI.  
Intrinsic sphincter deficiency predicted greater symptom improvement on one 
subjective instrument.  Urethral hypermobility was also an important prognostic 
factor, especially in patients undergoing vaginal suspension and midurethral sling 
simultaneously.  Following a MUS procedure, SUI symptoms may recur within 
two years of the surgery.  Although MUS procedures are typically safe and 
effective, clinicians are encouraged to provide additional preoperative counseling 
to those women who are at greatest risk for persistent or recurrent symptoms. 
 
Future research efforts to further elucidate the normal continence mechanism 
and the pathophysiology of stress urinary incontinence are needed.  Population-
based longitudinal observational studies would provide additional information 
about the natural history of SUI symptomatology.  Although there is some data to 
suggest that symptom recurrence occurs within two years of an MUS procedure, 
longer follow-up with multiple measures is needed to determine if this represents 
a post-operative plateau, or a sustained decline in treatment effect. 
 
The UDI-6 has proven to be an accurate instrument to measure subjective 
outcomes and has been widely adopted among clinician-researchers.19, 49, 56  
However, it is important to recognize that the 3 symptom domains (irritative, 
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obstructive and stress) all contribute equally to the UDI-6 score.  Studies whose 
primary aim is to determine SUI symptom improvement would be well-served to 
perform independent analyses using the UDI-6 stress subscale.  The 
administration of the entire UDI-6 is also important, though, as the incidence of 
de novo urgency following MUS is still in question and use of the irritative voiding 
subscale may provide new insight into this phenomenon.  Future studies should 
incorporate standardized clinical and outcome measures to further enhance the 
surgeon’s ability to provide appropriate therapeutic estimates for their patients 
undergoing midurethral sling procedures.  
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Tables & Figures 
 
 
 
Figure 4.1 Flowchart of study subjects 
 
 
 
 
 
551 patients were identified by 
surgical codes for MUS from 
May 2006 to December 2008 
and were mailed a survey 
225 Responses 
(40% response rate) 
37 Excluded 
14 vaginal obliterations 
8 wrong procedure 
7 repeat anti-incontinence 
procedure 
4 procidentia 
4 lack of pre-op survey 
188 Subjects included 
in analysis 
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Table 4.1 Comparison of postoperative survey responders and non-responders 
 
Table 4.1a Demographic and past medical characteristics 
 
 
 
Non-responders 
N=38 
Responders 
N=188   
  mean / percent mean / percent SD Range P value 
RP MUS 42% 48%     0.4 
TO MUS 58% 51%     0.4 
Characteristic           
Age, years 56 56.6 11.9 35-91 0.8 
BMI, kg/m2 28.1 28.2 5.8 18-59 0.9 
parity 2.1 2.5 1.3 0-8 0.07 
menopausal 64% 63%     0.9 
diabetes 17% 6%     0.03 
neurologic disease 8% 4%     0.1 
pulmonary disease 8% 16%     0.2 
anticholinergic medication 11% 5%     0.2 
adrenergic medication 18% 12%     0.3 
diuretic medication 21% 11%     0.08 
smoking (within 1 year) 14% 9%     0.4 
 
 
 
 
 
Table 4.1b Prior surgical procedures 
 
Non-responders 
N=38 
Responders 
N=188  P value 
Prior surgical procedures 
RP MUS 0% 0% 1.0 
TO MUS 0% 0% 1.0 
pubovaginal sling 3% 1% 0.4 
Burch 3% 3% 1.0 
urethral bulking 3% 0% 0.03 
anterior repair 0% 5% 0.2 
suspension 0% 1% 0.5 
hysterectomy 27% 23% 0.6 
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Table 4.1c Pre-operative urodynamic parameters 
 
 
 
Non-responders 
N=38 
Responders 
N=188   
  mean / percent mean / percent SD Range P value 
Urodynamic data           
Q-tip resting angle -0.3 0.9 16.9 -40 to 60 0.7 
straining angle 37.9 39.5 21.5 -25 to 85 0.7 
straining-resting angle 38.2 38.6 15.7 -6 to 80 0.9 
UHM (straining angle) 74% 75%   0.8 
UHM (S-R) 79% 77%   0.7 
MUCP 42.2 43.5 23.0 4-165 0.8 
ISD (MUCP≤20cmH20) 10% 13%   0.6 
LPP 43.9 87.8 28.0 27-187 0.8 
ISD (LPP≤60cmH20) 16% 11%   0.4 
PVR 18.8 30.7 39.2 0-225 0.07 
retention (PVR>100cc) 0% 7%   0.1 
urethral length 2.9 2.6 0.7 1-4.8 0.9 
Positive CST 100% 95%   0.2 
Destrusor Instability 9% 9%   0.9 
 
 
 
 
 
 
Table 4.1d Concomitant surgical procedures (anterior and apical) 
 
Non-responders 
N=38 
Responders 
N=188 P value  
Concomitant procedures       
anterior repair 32% 47% 0.07 
hysterectomy 24% 29% 0.5 
vaginal suspension (USLS) 8% 41% 0.04 
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Figure 4.2 Pre and post-operative QOL scores 
 
 
 
 
 
Table 4.2 Pre and post-operative QOL scores 
 
Pre-Op Post-Op Delta 
mean mean mean SD range 
UDI-6 46.1 22.9 -22.7 28 -100 to 50 
UIQ-7 36.1 13.0 -22.9 30 -100 to 67 
UDI-6 stress subscale 63.2 20.0 -40.0 41 -100 to 75 
UDI-6 Question 3 67.7 23.4 -45.8 46 -100 to 100 
46.1
36.1
63.2
67.7
22.9
13.0
20.0
23.4
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
UDI‐6 UIQ‐7 UDI Stress Question 3
Survey Score
UDI‐6 Question 3 "Do you experience urine leakage related to physical 
activity, coughing, or sneezing?"
Pre and Post Operative Symptom Scores
Pre Op Post Op
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Table 4.3 Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UDI-6 score (univariate) 
 
 
 
Δ UDI-6 (univariate) 
Factor mean Beta 95% CI P value 
follow-up ≤ 12 months referent 
follow-up 13-24 months   6.8 (-4.3, 17.8) 0.3 
follow-up ≥ 25 months   16.8 (5.3, 28.4) 0.005 
 
 
 
 
 
 
 
 
Table 4.4  Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UIQ-7 score (univariate) 
 
 
 
ΔUIQ - 7 (univariate) 
Factor mean Beta 95% CI P value 
BMI   0.7 (-.05, 1.5) 0.07 
pulmonary disease    10.6 (-1.3, 22.5) 0.08 
present -14       
absent -24       
ISD (MUCP≤20cmH20)    -19.0 (-33.4, -4.6) 0.01 
present -37       
absent -18       
follow-up ≤ 12 months referent 
follow-up 13-24 months   -9.3 (-21, 2.7) 0.13 
follow-up ≥ 25 months   -10.8 (-23.4, 1.7) 0.09 
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Table 4.5  Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UDI-6 stress subscale score 
(univariate) 
 
 
 
ΔUDI - 6 stress subscale (univariate) 
Factor mean Beta 95% CI P value 
age < 55 referent 
age 55-64   21.1 (7.0, 35.2) 0.004 
age ≥ 65   19.3 (4.4, 34.3) 0.01 
menopause*    17.9 (5.5, 30.3) 0.005 
present -33     
absent -51       
neurologic disease    26.8 (-4.3, 57.8) 0.09 
present -14     
absent -41       
straining angle*   -0.3 (-0.6, 0.01) 0.06 
S-R*   -0.6 (-1.0, -0.2) 0.007 
UHM (S-R)*    -16.0 (-31.6, -0.4) 0.04 
present -44     
absent -28       
PVR   0.13 (-0.2, 0.3) 0.10 
hysterectomy   12.3  (-0.9, 25.5) 0.07 
present -31     
absent -43       
suspension    19.5 (7.5, 31.6) 0.002 
present -29     
absent -49     
follow-up ≤ 12 months referent 
follow-up 13-24 months   17.1 (1.0, 33.3) 0.04 
follow-up ≥ 25 months   29.3 (12.5, 46.1) 0.001 
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Table 4.6 Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UDI-6 Question 3 score 
(univariate) 
 
 
 
ΔUDI-6 Question 3 (univariate) 
Factor mean Beta 95% CI P value 
age < 55 referent 
age 55-64   26.4 (10.7, 42.1) 0.001 
age ≥ 65   29.5 (12.9, 46.1) 0.001 
menopause*    24.4 (10.6, 38.3) 0.001 
present -37     
absent -61       
straining angle*   -0.4 (-0.7, -0.04) 0.03 
S-R*   -0.8 (-1.2, -0.3) 0.00 
UHM (S-R)*    -20.2 (-37.9, -2.5) 0.03 
present -50     
absent -30       
PVR   0.2 (0.003, 0.4) 0.05 
hysterectomy    13.4 (-1.4, 28.2) 0.08 
present -36     
absent -50       
suspension    23.4 (9.9, 37.0) <0.001 
present -33     
absent -56     
follow-up ≤ 12 months referent 
follow-up 13-24 months   14.2 (-4.1, 32.5) 0.10 
follow-up ≥ 25 months   30.7 (11.7, 49.7) 0.002 
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Table 4.7  Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UIQ-7 score (multivariable) 
 
 
 
ΔUIQ - 7 (multivariable) 
Factor Beta 95% CI P value 
BMI 0.6 (-0.3, 1.4) 0.20 
pulmonary disease 13.0 (0.3, 25.7) 0.05 
ISD (MUCP≤20cmH20) -16.3 (-30.7, -2.0) 0.03 
follow-up ≤ 12 months referent 
follow-up 13-24 months -9.8 (-22.7, 3.2) 0.14 
follow-up ≥ 25 months -12.9 (-25.9, 0.2) 0.05 
 
 
 
Table 4.8  Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UDI-6 stress subscale score 
(multivariable) 
 
 
 
ΔUDI - 6 stress subscale (multivariable) 
Factor Beta 95% CI P value 
age < 55 referent 
age 55-64 15.3 (0.8, 29.8) 0.04 
age ≥ 65 18.6 (3.1, 34.2) 0.02 
neurologic disease 22.1 (-7.7, 51.9) 0.15 
PVR 0.09 (-0.06, 0.2) 0.2 
hysterectomy -2.2 (-21.4, 16.9) 0.8 
suspension 16.6 (-1.7, 34.9) 0.08 
follow-up ≤ 12 months referent 
follow-up 13-24 months 8.3 (-8.6, 25.2) 0.3 
follow-up ≥ 25 months 22.7 (5.1, 40.3) 0.01 
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Table 4.9 Factors associated with persistent or improved symptoms following 
MUS, as measured by the change in UDI-6 Question 3 score 
(multivariable) 
 
 
 
ΔUDI-6 Question 3 (multivariable) 
Factor Beta 95% CI P value 
age < 55 referent 
age 55-64 21.0 (5.0, 37.1) 0.01 
age ≥ 65 26.0 (8.9, 43.1) 0.003 
PVR 0.1 (-0.03, .3) 0.1 
hysterectomy -5.3 (-26.1, 15.6) 0.6 
suspension 22.7 (2.5, 42.8) 0.03 
follow-up ≤ 12 months referent 
follow-up 13-24 months 4.1 (-14.5, 22.8) 0.6 
follow-up ≥ 25 months 23.8 (4.5, 43.1) 0.02 
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APPENDIX A 
 
Pelvic Floor Distress Inventory – Short Form 20 
 
Instructions: 
Please answer these questions by putting a X in the appropriate box.  If you are unsure about 
how to answer a question, give the best answer you can.  While answering these questions, 
please consider your symptoms over the last 3 months.  Thank you for your help. 
  
 
Name:__________________________________________Date:           /          /           
  
 
1. Do you usually experience pressure in the lower abdomen?                     ? No; ? Yes 
            0 
If yes, how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -      Moderately      -      Quite a bit 
 
2. Do you usually experience heaviness or dullness in the pelvic area?        ? No; ? Yes 
           0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
3. Do you usually have a bulge or something falling                                     ? No; ? Yes 
out that you can see or feel in the vaginal area?                                         0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
4. Do you usually have to push on the vagina or around the                        ? No; ? Yes 
rectum to have or complete a bowel movement?               0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
5. Do you usually experience a feeling of incomplete bladder emptying?     ? No; ? Yes 
           0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
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 6. Do you ever have to push up on a bulge in the vaginal                              ? No; ? Yes 
area with your fingers to start or complete urination?    0 
 
If yes, how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
7. Do you feel you need to strain too hard to have a bowel movement?       ? No; ? Yes 
                                                                                                                                    0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
  
8. Do you feel you have not completely emptied your bowels at the end of a bowel 
movement?  
                                                                                                                                 ? No; ? Yes 
If yes,  how much does this bother you?                   0 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
9. Do you usually lose stool beyond your control if your                                 ? No; ? Yes 
stool is well formed?         0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
  
10. Do you usually lose stool beyond your control if your                                 ? No; ? Yes 
stool is loose or liquid?         0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
11. Do you usually lose gas from the rectum beyond your control?                  ? No; ? Yes 
            0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
  
12. Do you usually have pain when you pass your stool?                                 ? No; ? Yes 
            0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
47 
 
 
  
13. Do you  experience a strong sense of urgency and have                           ? No; ? Yes 
              to rush to the bathroom to have a bowel movement?                                  0 
            
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
14. Does a part of your bowel ever pass through the rectum                            ? No; ? Yes 
and bulge outside during or after a bowel movement?     0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
15. Do you usually experience frequent urination?                                           ? No; ? Yes 
           0 
If yes, how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
                             Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
                                                                             
16. Do you usually experience urine leakage associated with a feeling of       ? No; ? Yes 
urgency, that is a strong sensation of needing to go to the bathroom?      0 
 
If yes, how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
17. Do you usually experience urine leakage related to coughing,                   ? No; ? Yes 
sneezing, or laughing?                                                                                  0 
 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
     
18. Do you usually experience small amounts of urine leakage                       ? No; ? Yes 
             (that is, drops)?          0 
If yes, how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
 
19. Do you usually experience difficulty emptying your bladder?                      ? No; ? Yes 
           0 
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
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 20. Do you usually experience pain or discomfort in the lower abdomen         ? No; ? Yes 
 or genital region?         0 
           
If yes,  how much does this bother you? 
   ? 1                  ? 2                 ? 3                 ? 4 
 Not at All     -     Somewhat     -     Moderately     -     Quite a bit 
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PELVIC FLOOR IMPACT QUESTIONNAIRE – SHORT FORM 7 
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